Cargando…

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody

PURPOSE: RG7116 is a novel anti-HER3 therapeutic antibody that inhibits HER3 signalling and induces antibody-dependent cellular cytotoxicity of tumor cells due to a glycoengineered antibody Fc moiety. We investigated the efficacy and pharmacokinetic/pharmacodynamic properties of HER3 signal inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meneses-Lorente, Georgina, Friess, Thomas, Kolm, Irene, Hölzlwimmer, Gabriele, Bader, Sabine, Meille, Christophe, Thomas, Marlene, Bossenmaier, Birgit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365277/ https://www.ncbi.nlm.nih.gov/pubmed/25702049 http://dx.doi.org/10.1007/s00280-015-2697-8

Ejemplares similares

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
por: Herting, Frank, et al.
Publicado: (2014)

Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
por: Luo, Cheng, et al.
Publicado: (2017)

The Applications of Metabolic Glycoengineering
por: Ying, Liwei, et al.
Publicado: (2022)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women()
por: Clifford, Gary M., et al.
Publicado: (2019)

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
por: Bauer, Sebastian, et al.
Publicado: (2021)

Genetic glycoengineering in mammalian cells
por: Narimatsu, Yoshiki, et al.
Publicado: (2021)

Strategies for Glycoengineering Therapeutic Proteins
por: Dammen-Brower, Kris, et al.
Publicado: (2022)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Cyclopropene derivatives of aminosugars for metabolic glycoengineering
por: Hassenrück, Jessica, et al.
Publicado: (2019)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
por: Adler-Moore, Jill, et al.
Publicado: (2019)

Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
por: Li, Wei, et al.
Publicado: (2017)

Direct quality control of glycoengineered erythropoietin variants
por: Čaval, Tomislav, et al.
Publicado: (2018)

Applying Acylated Fucose Analogues to Metabolic Glycoengineering
por: Rosenlöcher, Julia, et al.
Publicado: (2015)

Protein Glycoengineering: An Approach for Improving Protein Properties
por: Ma, Bo, et al.
Publicado: (2020)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

Design of Glycoengineered IL-4 Antagonists Employing Chemical and Biosynthetic Glycosylation
por: Thomas, Sarah, et al.
Publicado: (2023)

Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
por: Song, Kyoung, et al.
Publicado: (2014)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
por: Tytgat, Hanne L. P., et al.
Publicado: (2019)

A versatile design platform for glycoengineering therapeutic antibodies
por: Ludwig, Seth D., et al.
Publicado: (2022)

Cell-Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein
por: Ruhnau, Johannes, et al.
Publicado: (2021)

Deciphering the Stepwise Binding Mode of HRG1β to HER3 by Surface Plasmon Resonance and Interaction Map
por: Peess, Carmen, et al.
Publicado: (2015)

IgG-Fc glycoengineering in non-mammalian expression hosts
por: Loos, Andreas, et al.
Publicado: (2012)

Labeling glycans on living cells by a chemoenzymatic glycoengineering approach
por: Almaraz, Ruben T., et al.
Publicado: (2017)

Glycoengineering Chinese hamster ovary cells: a short history
por: Donini, Roberto, et al.
Publicado: (2021)

Glycoengineering artificial receptors for microglia to phagocytose Aβ aggregates
por: Yu, Dongqin, et al.
Publicado: (2021)

The Impact of Glycoengineering on the Endoplasmic Reticulum Quality Control System in Yeasts
por: Piirainen, Mari A., et al.
Publicado: (2022)

Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering
por: Saunders, Matthew J., et al.
Publicado: (2023)

A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease
por: Song, Liang, et al.
Publicado: (2017)

Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease
por: Liang, Hai-Yong, et al.
Publicado: (2021)

Allopregnanolone Preclinical Acute Pharmacokinetic and Pharmacodynamic Studies to Predict Tolerability and Efficacy for Alzheimer’s Disease
por: Irwin, Ronald W., et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of (S)-Ketoprofen Co-Administered with Caffeine: A Preclinical Study in Arthritic Rats
por: Medina-López, Raúl, et al.
Publicado: (2018)

Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors
por: Gartlan, Kate H., et al.
Publicado: (2022)

Investigating Cell Surface Galectin-Mediated Cross-Linking on Glycoengineered Cells
por: Belardi, Brian, et al.
Publicado: (2012)

N-Propionylmannosamine: using biochemical glycoengineering to promote peripheral nerve regeneration
por: Koulaxouzidis, Georgios, et al.
Publicado: (2015)

A novel low-parameter computational model to aid in-silico glycoengineering
por: Spahn, Philipp N, et al.
Publicado: (2015)

Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines
por: Price, Nancy L., et al.
Publicado: (2016)

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
por: Termini, James M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rospidtr7tn5ekhcchh6a5p4v7